|
|
| | tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate Basic information |
| Product Name: | tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate | | Synonyms: | Edoxaban INTERMEDIATES Ⅱ;Edoxaban INTERMEDIATES Ⅲ;InterMediate of Edoxaban;Tert-Butyl [(1R,2S,5S)-2-aMino-5-[(diMethylaMino)carbonyl]cyclohexyl]carbaMate(for Edoxaban);Carbamic acid, N-[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester, ethanedioate (1:1);N-[(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl] -, 1,1-dimethylethyl ester;D-1315;(5H-Pyrrolo[3,4-d]thiazole-5-carboxylic acid,2-[[[(1R,2S,5S)-2-[[(5-chloro-1H-indol-2-yl)carbonyl]aMino]-5-[(diMethylaMino)carbonyl]cyclohexyl]aMino]carbonyl]-4,6-dihydro-,1,1-diMethylethyl ester | | CAS: | 365998-36-3 | | MF: | C14H27N3O3 | | MW: | 285.38 | | EINECS: | 1592732-453-0 | | Product Categories: | | | Mol File: | 365998-36-3.mol |  |
| | tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate Chemical Properties |
| Boiling point | 434.4±45.0 °C(Predicted) | | density | 1.09±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C(protect from light) | | form | Solid | | pka | 11.90±0.60(Predicted) | | CAS DataBase Reference | 365998-36-3 |
| | tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate Usage And Synthesis |
| Description | Tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate is a pharmaceutical intermediate compound used in the preparation of Edoxaban. Edoxaban is an oral anticoagulant drug used for the treatment of strokes due to blood clots, thrombosis, heart disease and cirrhosis of the liver. | | Uses | Tert-butyl(1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate is an organic synthesis intermediates and pharmaceutical intermediates, which can be used in laboratory research and development processes and chemical and pharmaceutical synthesis processes. It is a reagent used in the synthesis of cis-1,2-diaminocyclohexane derivative. It is also mainly used as raw material to synthesize reversible factor Xa inhibitor drug edoxaban[1]. The drug has been approved by the U.S. Food and Drug Administration as a direct oral anticoagulant and is the fourth direct oral anticoagulant approved for clinical use[2-3].
Referance：[1] Frantisek Nehaj, Juraj Sokol, Jela Ivankova, Michal Mokan, Marian Mokan, Jan Stasko, Edoxaban affects TRAP-dependent platelet aggregation, Journal of Thrombosis and Thrombolysis, 2020, 49, 578-583.
[2] Juraj Sokol, Frantisek Nehaj, Jela Ivankova, Michal Mokan, Lenka Lisa, Jana Zolkova, Lubica Vadelova, Marian Mokan, Jan Stasko, Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation,Clinical and Applied Thrombosis/Hemostasis, 2020.
[3] Mara Poulakos, Jacqueline N Walker, Umima Baig, Tosin David, Edoxaban: A direct oral anticoagulant, American Journal of Health-System Pharmacy, 2017,74, 117–129. |
| | tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate Preparation Products And Raw materials |
| Raw materials | Edoxaban Impurity 16-->(1S,4S,5S)-4-Bromo-6-oxabicyclo[3.2.1]octan-7-one-->(1R,2R,4S)-2-[(tert-butoxycarbonyl)aMino]-4-[(diMethylaMino)carbonyl]cyclohexyl Methanesulfonate-->carbamic acid, n-[(1r,2r,5s)-5-[(dimethylamino)carbonyl]-2-hydroxycyclohexyl]-, 1,1-dimethylethyl ester-->(1S,3R,4R)-3-amino-4-hydroxy-N,N-dimethylcyclohexanecarboxamide-->Di-tert-butyl dicarbonate-->(1S,3S,6R)-N,N-dimethyl-7-oxabicyclo[4.1.0]heptane-3-carboxamide | | Preparation Products | EthanediaMide iMpurity F-->EthanediaMide iMpurity D |
|